Market News & Trends
ValenzaBio Partners With ProBioGen to Maximize Cell Line Productivity & Licenses GlymaxX
ProBioGen and ValenzaBio recently announced the initiation of a cell line development project involving the application of ProBioGen's proprietary GlymaxX technology. ValenzaBio's VB119 is a…
LEXEO Therapeutics Receives Rare Pediatric Disease Designation & Orphan Drug Designation
LEXEO Therapeutics recently announced that the US FDA has granted Rare Pediatric Disease designation and Orphan Drug designation to LX1004 for the treatment of CLN2…
Catalent Launches New OptiDose Design Solution to Help Create Differentiated Treatments That Are Successful for Innovators, Patients & Health Care Professionals
Catalent recently announced the launch of its new OptiDose Design Solution, at the Controlled Release Society (CRS) annual meeting, which is took place virtually from July…
AMRI Becomes Curia
Albany Molecular Research, Inc. (AMRI), a leading global contract research, development and manufacturing organization serving the pharmaceutical and biopharmaceutical industries, today announced that it is…
Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and…
Strathclyde University conclude that membrane technology could revolutionize vaccine and therapeutics production
Whilst paying tribute to to the hugely impressive efforts of those who reconfigured existing equipment at speed into a "Generation 1" manufacturing process for mRNA…
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve ZydisR Formulation for Cannabidiol as an Anesthesia Premedication Catalent, the leading global provider of advanced delivery…
Curia, the former AMRI, to Acquire Integrity Bio, Expanding Its Biologic Formulation and Fill-Finish Capabilities
One day after announcing its name change to Curia, leading contract research, development and manufacturing organization AMRI reported it has entered into a definitive agreement…
SPI Pharma launches UltraBurst™, the first in class preformulated platform for flash orally dispersible tablets.
SPI Pharma introduces UltraBurst™, providing a step-change in the most critical orally disintegrating tablet (ODT) characteristics — dissolution time. It is an innovative excipient platform…
Collaboration Between AbbVie, Biogen & Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health & Disease
Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….